Self-resolution of Epstein-Barr virus-associated B-cell lymphoma in a patient with dermatomyositis following withdrawal of mycophenolate mofetil and methotrexate

Journal of the American Academy of Dermatology

Volumn 51, Issue 2, 2004, Pages 124-130

  Waldman, Mark A ^a   Callen, Jeffrey P ^a  

^a University of Louisville School of Medicine   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HYDROCORTISONE; IMMUNOGLOBULIN; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PIMECROLIMUS; PREDNISONE; CHLOROQUINE; DAPSONE; DEXAMETHASONE; HYDROXYCHLOROQUINE SULFATE; THALIDOMIDE; DRUG DERIVATIVE; IMMUNOSUPPRESSIVE AGENT; MYCOPHENOLIC ACID;

ADULT; ARTICLE; B CELL LYMPHOMA; BRAIN LYMPHOMA; CANCER DIAGNOSIS; CASE REPORT; CLINICAL FEATURE; CONVALESCENCE; DERMATOMYOSITIS; EPSTEIN BARR VIRUS; FEMALE; HUMAN; HUMAN TISSUE; LABORATORY DIAGNOSIS; PRIORITY JOURNAL; PSYCHOSIS; SKIN BIOPSY; BRAIN BIOPSY; COMPUTER ASSISTED TOMOGRAPHY; DISEASE COURSE; DRUG ERUPTION; DRUG WITHDRAWAL; ELECTROMYOGRAM; FOLLOW UP; HISTOLOGY; LABORATORY TEST; MAMMOGRAPHY; MUSCLE BIOPSY; NUCLEAR MAGNETIC RESONANCE IMAGING; THORAX RADIOGRAPHY; BIOPSY; BRAIN TUMOR; BURKITT LYMPHOMA; MALE; MIDDLE AGED; REMISSION; REVIEW; TREATMENT WITHDRAWAL;

BIOPSY; BRAIN NEOPLASMS; BURKITT LYMPHOMA; DERMATOMYOSITIS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MAGNETIC RESONANCE IMAGING; MALE; METHOTREXATE; MIDDLE AGED; MYCOPHENOLIC ACID; PREDNISONE; REMISSION INDUCTION; WITHHOLDING TREATMENT;

EID: 3242721598     PISSN: 01909622     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jaad.2004.03.020     Document Type: Article

References (44)

1. DeAngelis L.M. Brain tumors. N Engl J Med. 344:2001;114-123
2. Viraben R., Brousse P., Lamant L. Reversible cutaneous lymphoma occurring during methotrexate therapy. Br J Dermatol. 135:1996;116-118
3. Kamel O.W., van de Rijn M., Weiss L.M., Del Zoppo G.J., Hench P.K., Robbins B.A., et al. Brief Report: Reversible lymphomas associated with Epstein-Barr virus occurring during methotrexate therapy for rheumatoid arthritis and dermatomyositis. N Engl J Med. 328:1993;1317-1321
4. Daswon T.M., Starkebaum G., Wood B.L., Willkens R.F., Gown A.M. Epstein-Barr virus, methotrexate, and lymphoma in patients with rheumatoid arthritis and primary Sjogren's syndrome: Case series. J Rheumatol. 28:2001;47-53
5. Tournadre A., D'Incan M., Dubost J.J., Franck F., Dechelotte P., Souteyrand P., et al. Cutaneous lymphoma associated with Epstein-Barr virus infection in 2 patients with methotrexate. Mayo Clin Proc. 76:2001;845-848
6. Kamel O.W., van de Rijn M., LeBrun D.P., Weiss L.M., Warnke R.A., Dorfman R.F. Lymphoid neoplasms in patients with rheumatoid arthritis and dermatomyositis: Frequency of Epstein-Barr virus and other features associated with immunosuppression. Human Pathol. 25:1994;638-643
7. Chai C., White W.L., Shea C.R., Prieto V.G. Epstein Barr virus-associated lymphoproliferative-disorders primarily involving the skin. J Cutan Pathol. 26:1999;242-247
8. Chow W.-H., Gridley G., Mellemkjar L., McLaughlin J.K., Olsen J.H., Fraumeni J.F. Cancer risk following polymyositis and dermatomyositis: a nationwide cohort study in Denmark. Cancer Causes Control. 6:1995;9-13
9. Stockton D., Doherty V.R., Brewster D.H. Risk on cancer in patients with dermatomyositis or polymyositis, and follow-up implications: a Scottish population-based cohort study. Br J Cancer. 85:2001;41-45
10. Hill C.L., Zhang Y., Sigurgeirsson B., Pukkala E., Mellemkjaer L., Airio A., et al. Frequency of specific cancer types in dermatomyositis and polymyositis: a population-based study. Lancet. 357:2001;96-100
11. Airio A., Pukkala E., Isomaki H. Elevated cancer incidence in patients with dermatomyositis: A population based study. J Rheumatol. 22:1995;1300-1303
12. Buchbinder R., Hill C.L. Malignancy in patients with inflammatory myopathy. Curr Rheum Reports. 4:2002;415-426
13. Salloum E., Cooper D.L., Howe G., Lacy J., Tallini G., Crouch J., et al. Spontaneous regression of lymphoproliferative disorders in patients treated with methotrexate for rheumatoid arthritis and other rheumatic diseases. J Clin Oncol. 14:1996;1943-1949
14. Buchbinder R., Forbes A., Hall S., Dennett X., Giles G. Incidence of malignant disease in biopsy-proven inflammatory myopathy: A population-based cohort study. Ann Intern Med. 134:2001;1087-1095
15. Moder K.G., Tefferi A., Menke D.M., Luthra H.S. hematologic malignancies and the use of methotrexate in rheumatoid arthritis: A retrospective study. Am J Med. 99:1995;276-281
16. Kremer J.M., Lee J.K. The safety and efficacy of the use of methotrexate in long-term therapy for rheumatoid arthritis. Arthritis Rheum. 29:1986;822-831
17. Hazelman B. Incidence of neoplasms in patients with rheumatoid arthritis exposed to different treatment regimens. Am J Med. 78:1985;39-43
18. Weinstein A., Marlowe S., Korn J., Farouhar F. Low-dose methotrexate treatment of rheumatoid arthritis: long term observation. Am J Med. 79:1985;331-337
19. Ellman M.H., Jurwitz H., Thomas C., Kozloff M. Lymphoma developing in a patient with rheumatoid arthritis taking low dose weekly methotrexate. J Rheumatol. 18:1991;1741-1743
20. Usman A.R., Yunus M.B. Non-Hodgkin's lymphoma in patients with rheumatoid arthritis treated with low dose methotrexate. J Rheumatol. 23:1996;1095-1097
21. Lim I.G.S., Bertouch J.V. Remission of lymphoma after drug withdrawal in rheumatoid arthritis. MJA. 177:2002;500-501
22. Mariette X., Casals-Hatem D., Warszawki J., Liote F., Balandraud N., Sibilia J. Lymphomas in rheumatoid arthritis patients treated with methotrexate: a 3-year prospective study in France. Blood. 99:2001;3909-3915
23. Baird R.D., van Zyl-Smit R.N., Dilke T., Scaott S.E., Rassam S.M. Spontaneous remission of low-grade B-cell non-Hodgkin's lymphoma following withdrawal of methotrexate in a patient with rheumatoid arthritis: case report and review of the literature. Br J Dermatol. 118:2002;567-568
24. Bachman T.R., Sawitzke A.D., Perkins S.L., Ward J.H., Cannon G.W. Methotrexate-associated lymphoma in patients with rheumatoid arthritis: report of two cases. Arthritis Rheum. 39:1996;325-329
25. Delaporte E., Catteau B., Cardon T., Flipo R.M., Lecomte-Houcke M., Piette F., et al. Pseudolymphome cutane au cours du traitement d'une poyarthrite rhymatoide par le methotrexate a faibles doses. Ann Dermatol Venereol. 122:1995;521-525
26. Davies J.M.S., Kremer J.M., Furst D.E., Eastman A. Lymphomatous changes during methotrexate therapy. Arthritis Rheum. 38:1995;S204
27. Georgescu L., Quinn G.C., Schwartzman S., Paget S.A. Lymphoma in patients with rheumatoid arthritis: association with the disease state or methotrexate treatment. Semin Arthritis Rheum. 26:1997;794-804
28. Williams C.A., Bloch D.A., Sibley J., Haga M., Wolfe F., Raynauld J.-P., et al. Lymphoma and leukemia in rheumatoid arthritis: Are they associated with azathiaprine, cyclophosphamide, or methotrexate? A matched case-control study in the Arthritis, Rheumatism and Aging Medical Information System (ARAMIS) population. J Clin Rheum. 2:1996;64-72
29. Shiroky J.B., Frost A., Skelton J.D., Haegert D.G., Newkirk M.M., Neville C. Complications of immunosuppression associated with weekly low dose methotrexate. J Rheumatol. 18:1991;1172-1175
30. Sigurgeirsson B., Lindelof B., Edhag O., Allander E. Risk of cancer in patients with dermatomyositis or polymyositis. A population-based study. N Engl J Med. 326:1992;363-367
31. Basset-Seguin N., Roujeau J.C., Gherardi R., Guillame J.C., Revuz J., Touraine R. Prognostic factors and predictive signs of malignancy in adult dermatomyositis. Arch Dermatol. 126:1990;633-637
32. Zantos D., Zhang Y., Felson D. The overall and temporal association of cancer with polymyositis and dermatomyositis. J Rheumatol. 21:1994;1855-1859
33. Callen J.P. Dermatomyositis. Lancet. 355:2000;53-57
34. Marie I., Hachulla E., Hatron P.Y., Hellot M.F., Levesque H., Devulder B., et al. Polymyositis and dermatomyositis: Short term and longterm outcome, and predictive factors of prognosis. J Rheumatol. 28:2001;2230-2237
35. Liote F., Pertuiset E., Cochand-Priollet B., D'Agay M.F., Dombret J., Numeric P., et al. Methotrexate related B lymphoproliferative disease in a patient with rheumatoid arthritis. Role of Epstein-Barr virus infection. J Rheumatol. 22:1995;1174-1177
36. Bittar B.F., Rose C.D. Early development of Hodgkin's lymphoma in association with the use of methotrexate for the treatment of dermatomyositis. Ann Rheum Disease. 54:1995;607-608
37. Paul D., LeTourneau A., Cayeula J.M., Devidas A., Robert C., Molinie V., et al. Epstein-Barr virus-associated lymphoproliferative disease during methotrexate therapy for psoriasis. Arch Dermatol. 133:1997;867-871
38. Kingsmore S.F., Hall B.D., Allen N.B., Rice J.R., Caldwell D.S. Association of methotrexate, rheumatoid arthritis and lymphoma: Report of 2 cases and literature review. J Rheumatol. 19:1992;1462-1465
39. Chevrel G., Berger R., Miossec P., Blanc M., Jeanneret J., Felman C., et al. Hodgkin's disease and B cell lymphoproliferation in rheumatoid arthritis patients treated with methotrexate: A kinetic study of lymph node changes. Arthritis and Rheum. 42:1999;1773-1776
40. Kleiman K.S., Mahowald M.L. Methotrexate and lymphoma: A presentation of four cases and review of the literature. J Clin Rheumatol. 4:1998;254-259
41. Ferracioli G.F., Casatta L., Bartoli E., DeVita S., Dolcetti R., Boiocchi M., et al. Epstein-Barr virus-associated Hodgkin's lymphoma in a rheumatoid arthritis patient treated with methotrexate and cyclosporin A. Arthritis Rheum. 38:1995;867-868
42. Sukenik S., Ariad S., Flusser D. Malignancy in patient with rheumatoid arthritis treated with methotrexate. J Rheumatol. 24:1997;806-807
43. Hirose Y., Masaki Y., Okada J., Kim C.G., Kawabata H., Ogawa N. Epstein-Barr virus-associated lymphoma with concurrent p53 protein expression in a rheumatoid arthritis patient treated with methotrexate. Int J Hematol. 75:2002;412-415
44. Jardine D.L., Colls B.M. Hodgkin's disease following methotrexate therapy for rheumatoid arthritis. NZ Med J. 115:2002;294-295